#2846 DEVELOPMENT OF THE JAPANESE VERSION OF THE BASEL ASSESSMENT OF ADHERENCE TO IMMUNOSUPPRESSIVE MEDICATIONS SCALE

Abstract Background and Aims One of the major barriers for long-term transplant outcomes in kidney recipients is medication non-adherence, which a risk factor de novo donor-specific antibody development leading to antibody-mediated rejection graft loss. Identifying non-adherent patients first step minimizing complications non-adherence. However, date, there no validated Japanese self-report instrument evaluate MA patients. This study aimed determine reliability validity version Basel Assessment Adherence Immunosuppressive Medications Scale (J-BAASIS). Method We conducted single-center cross-sectional who visited our hospital. The eligible willing participants were randomly assigned two groups, J-BAASIS group J-BAASIS+MEMS group, with random numbers generated by computer. All filled out questionnaire including (the survey). They again similar conditions during their following outpatient visit 4-6 weeks later second took methylprednisolone tablets daily using MEMS until survey. analyzed (test-retest measurement error) (concurrent event monitoring system (MEMS) 12-item Medication Scale) referring COSMIN Risk Bias tool. Results A total 106 56; 50) included this study. In analysis test-retest reliability, Cohen's kappa coefficient was 0.62. error, positive negative agreement 0.78 0.84, respectively. concurrent MEMS, sensitivity specificity 0.84 0.90, Scale, point-biserial correlation “medication compliance” subscale 0.38 (p<0.001). Conclusion determined have good validity. Using adherence may help clinicians identify institute appropriate corrective measures improve outcomes. Moreover, study, demonstrated gold standard measuring adherence, further strengthens evidence psychometric properties original BAASIS.